Trehalose Boosts Macrophage Ability to Clear Plaques
|
By LabMedica International staff writers Posted on 22 Jun 2017 |

Image: A photomicrograph of a cross section of a mouse aorta, the main artery in the body, with a large plaque. Straight red lines toward the upper left are the wall of the aorta. Yellow areas are where housekeeping cells called macrophages are clearing cellular waste (Photo courtesy of Ismail Sergin, Washington University School of Medicine).
Cardiovascular disease researchers working with mouse models have found that treatment with the sugar trehalose boosts the activity of the macrophages responsible for clearing the molecular and cellular debris that make up atherosclerotic plaques.
Macrophages specialize in removing lipids and debris present in atherosclerotic plaques. However, as plaques grow, their size and complexity render macrophages unable to degrade exogenous atherogenic material and endogenous cargo including dysfunctional proteins and organelles. The decline in the autophagy-lysosome system that contributes to this situation is evidenced by disarray of key autophagy markers in both mouse and human atherosclerotic plaques.
Investigators at Washington University School of Medicine (St. Louis, MO, USA) reported that by boosting the activity of the macrophage protein transcription factor EB (TFEB), they could reverse the autophagy dysfunction of macrophages in plaques. TFEB is known to regulate many lysosomal genes, and by translocating to the cell nucleus, TFEB itself can be activated when the lysosome malfunctions. This serves to regulate both the abundance of lysosomes found in the cell and their ability to degrade complex molecules.
The investigators described in the June 7, 2017, online edition of the journal Nature Communications the ability of the natural sugar trehalose to act as an inducer of macrophage autophagy-lysosomal biogenesis and demonstrated the ability of trehalose to stimulate the plaque clearing properties of macrophage TFEB overexpression.
Trehalose is a non-reducing natural disaccharide (alpha,alpha-1,1-glucoside) synthesized endogenously by non-mammalian organisms such as insects, crustaceans, and certain plants. Present in high concentration in these organisms, trehalose is thought to provide protection against environmental stresses such as osmotic and temperature shocks by stabilizing biomolecules. The pharmaceutical industry uses trehalose as a stabilizer in numerous medicines. In the food industry, trehalose has been used as a sweetener because of its mild sweetness as compared to its other closely related non-reducing disaccharide sucrose. Owing to the ability of trehalose to induce autophagy and ameliorate various protein aggregation neurodegenerative diseases and the finding of TFEB as an autophagy inducer particularly of protein aggregates, the investigators became interested in evaluating the effects of trehalose in the induction of macrophage TFEB, autophagy-lysosomal biogenesis, and atherosclerosis.
Toward this end, they injected mice prone to atherosclerosis with trehalose. Following treatment, these animals displayed reduced plaque in their arteries. The sizes of the plaques measured in the aortic root were variable, but on average, the plaques measured 0.35 square millimeters in control mice compared with 0.25 square millimeters in the mice receiving trehalose, which translated into a roughly 30% decrease in plaque size. The effect disappeared when the mice were given trehalose orally or when they were injected with other types of sugar, even those with similar structures.
"We are interested in enhancing the ability of these immune cells, called macrophages, to degrade cellular garbage - making them super-macrophages," said senior author Dr. Babak Razani, assistant professor of medicine at Washington University School of Medicine. "In atherosclerosis, macrophages try to fix damage to the artery by cleaning up the area, but they get overwhelmed by the inflammatory nature of the plaques. Their housekeeping process gets gummed up. So their friends rush in to try to clean up the bigger mess and also become part of the problem. A soup starts building up - dying cells, more lipids. The plaque grows and grows."
"Trehalose is not just enhancing the housekeeping machinery that is already there," said Dr. Razani. "It is triggering the cell to make new machinery. This results in more autophagy - the cell starts a degradation fest. Is this the only way that trehalose works to enhance autophagy by macrophages? We cannot say that for sure - we are still testing that. But is it a predominant process? Yes."
Related Links:
Washington University School of Medicine
Macrophages specialize in removing lipids and debris present in atherosclerotic plaques. However, as plaques grow, their size and complexity render macrophages unable to degrade exogenous atherogenic material and endogenous cargo including dysfunctional proteins and organelles. The decline in the autophagy-lysosome system that contributes to this situation is evidenced by disarray of key autophagy markers in both mouse and human atherosclerotic plaques.
Investigators at Washington University School of Medicine (St. Louis, MO, USA) reported that by boosting the activity of the macrophage protein transcription factor EB (TFEB), they could reverse the autophagy dysfunction of macrophages in plaques. TFEB is known to regulate many lysosomal genes, and by translocating to the cell nucleus, TFEB itself can be activated when the lysosome malfunctions. This serves to regulate both the abundance of lysosomes found in the cell and their ability to degrade complex molecules.
The investigators described in the June 7, 2017, online edition of the journal Nature Communications the ability of the natural sugar trehalose to act as an inducer of macrophage autophagy-lysosomal biogenesis and demonstrated the ability of trehalose to stimulate the plaque clearing properties of macrophage TFEB overexpression.
Trehalose is a non-reducing natural disaccharide (alpha,alpha-1,1-glucoside) synthesized endogenously by non-mammalian organisms such as insects, crustaceans, and certain plants. Present in high concentration in these organisms, trehalose is thought to provide protection against environmental stresses such as osmotic and temperature shocks by stabilizing biomolecules. The pharmaceutical industry uses trehalose as a stabilizer in numerous medicines. In the food industry, trehalose has been used as a sweetener because of its mild sweetness as compared to its other closely related non-reducing disaccharide sucrose. Owing to the ability of trehalose to induce autophagy and ameliorate various protein aggregation neurodegenerative diseases and the finding of TFEB as an autophagy inducer particularly of protein aggregates, the investigators became interested in evaluating the effects of trehalose in the induction of macrophage TFEB, autophagy-lysosomal biogenesis, and atherosclerosis.
Toward this end, they injected mice prone to atherosclerosis with trehalose. Following treatment, these animals displayed reduced plaque in their arteries. The sizes of the plaques measured in the aortic root were variable, but on average, the plaques measured 0.35 square millimeters in control mice compared with 0.25 square millimeters in the mice receiving trehalose, which translated into a roughly 30% decrease in plaque size. The effect disappeared when the mice were given trehalose orally or when they were injected with other types of sugar, even those with similar structures.
"We are interested in enhancing the ability of these immune cells, called macrophages, to degrade cellular garbage - making them super-macrophages," said senior author Dr. Babak Razani, assistant professor of medicine at Washington University School of Medicine. "In atherosclerosis, macrophages try to fix damage to the artery by cleaning up the area, but they get overwhelmed by the inflammatory nature of the plaques. Their housekeeping process gets gummed up. So their friends rush in to try to clean up the bigger mess and also become part of the problem. A soup starts building up - dying cells, more lipids. The plaque grows and grows."
"Trehalose is not just enhancing the housekeeping machinery that is already there," said Dr. Razani. "It is triggering the cell to make new machinery. This results in more autophagy - the cell starts a degradation fest. Is this the only way that trehalose works to enhance autophagy by macrophages? We cannot say that for sure - we are still testing that. But is it a predominant process? Yes."
Related Links:
Washington University School of Medicine
Latest BioResearch News
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
Simple One-Hour Saliva Test Detects Common Cancers
Early detection is critical for improving cancer outcomes, yet many diagnostic tests rely on invasive procedures such as blood draws or biopsies. Researchers are exploring simpler approaches that could... Read more
Blood Test Could Help Guide Treatment Decisions in Germ Cell Tumors
Chemotherapy is often highly effective for germ cell tumors, but in a subset of patients, the disease does not respond well to standard treatment. For these individuals, doctors may consider high-dose... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
New Imaging Approach Could Help Predict Dangerous Gut Infection
Clostridioides difficile infections affect roughly half a million people in the United States each year and are a leading cause of infectious diarrhea in healthcare settings. The bacterium can trigger... Read more
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







